Can we alter the natural history of Crohn disease in children?

Journal of Pediatric Gastroenterology and Nutrition

Volumn 40, Issue 3, 2005, Pages 262-272

  Hyams, Jeffrey S ^a   Markowitz, James F ^b  

^a Farmington   (United States)

^b NONE

Author keywords

Children; Corticosteroids; Crohn disease; Immunomodulators; Infliximab; Natural history

Indexed keywords

ADALIMUMAB; ALICAFORSEN; AZATHIOPRINE; BETA INTERFERON; BUDESONIDE; CD4 ANTIGEN; CORTICOSTEROID; GAMMA INTERFERON ANTIBODY; GROWTH HORMONE; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 11; INTERLEUKIN 12 ANTIBODY; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; MLN 02; NATALIZUMAB; ONERCEPT; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SEMAPIMOD; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AGE DISTRIBUTION; ARTHRALGIA; CHILDHOOD DISEASE; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG SAFETY; DYSPNEA; FLUSHING; HEADACHE; HUMAN; INTESTINE SURGERY; LEUKOPENIA; LIVER TOXICITY; LYMPHOMA; MORBIDITY; NAUSEA; PATHOGENESIS; PHYSICAL DISEASE; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; REVIEW; SOCIAL ADAPTATION; STOMATITIS; SYMPTOMATOLOGY; VOMITING;

6-MERCAPTOPURINE; ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CHILD; CROHN DISEASE; DISEASE-FREE SURVIVAL; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE;

EID: 14844331036     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MPG.0000154660.62359.FE     Document Type: Review

References (132)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
2. Farmer RG, Hawk WA, Turnbull RB. Clinical patterns in Crohn's disease. A statistical study of 615 cases. Gastroenterology 1975; 68:627-35.
3. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease: relationships between the clinical pattern and prognosis. Gastroenterology 1985;88:1818-25.
4. Griffiths AM, Wesson DE, Shandling B, et al. Factors influencing postoperative recurrence of Crohn's disease in childhood. Gut 1991;32:491-5.
5. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the working party for the World Congress of Gastroenterology, Vienna, 1998. Inflamm Bowel Dis 2000;6:8-15.
6. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50.
7. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
8. Veloso FT, Ferreira JT, Barros L. et al. Clinical outcome of Crohn's disease: analysis according to the Vienna classification and clinical activity. Inflamm Bowel Dis 2001;7:306-13.
9. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002;122: 867-74.
10. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002;122:854-66.
11. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-8.
12. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002;359:1661-5.
13. Vermeire S, Wild G, Kocher K, et al. CARD 15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 2002;71:74-83.
14. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002;123:679-88.
15. Bonen DK, Ogura Y, Nicolae DL, et al. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 2003;124:140-6.
16. Inoue N, Tamura K, Kinouchi Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002;123:86-91.
17. Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002;123:106-11.
18. Mascheretti S, Hampe J, Croucher PJ, et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15(NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP level trials. Pharmacogenetics 2002;12:509-15.
19. Giallourakis C, Stoll M, Miller K, et al. IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn disease and identification of a novel association with ulcerative colitis. Am J Hum Genet 2003;73:205-11.
20. Armuzzi A, Ahmad T, Ling KL, et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 2003;52:1133-9.
21. Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998;115:822-9.
22. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000; 47:487-96.
23. Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996;110: 1810-9.
24. Desir B, Amre DK, Lu SE, et al. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol 2004;2;139-46.
25. Teml A, Kratzer V, Schneider B, et al. Anti-saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol 2003;98:2226-31.
26. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004;126:414-24.
27. Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004;53:1117-22.
28. Vermeire S, Joossens S, Peelers M. et al. Comparative study of ASCA (Anti-saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001;120:827-9.
29. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-69.
30. Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60.
31. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993;104:1293-301.
32. Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology 1999;116:521-6.
33. Griffiths A, Koletzko S, Sylvester F, et al. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease. J Pediatr Gastroenterol Nutr 1993;17:186-92.
34. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.
35. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-8.
36. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996;110:45-51.
37. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
38. Franchimont DP, Louis E, Croes F, et al. Clinical pattern of corticosteroid dependent Crohn's disease. Eur J Gastroenterol Hepatol 1998;10:821-5.
39. Bantel H, Schmitz ML, Raible A, et al. Critical role of NF-κB and stress-activated protein kinases in steroid unresponsiveness. FASEB J 2002;16:1832-4.
40. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein-170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000;118: 279-88.
41. Flood L, Lofberg R, Stierna P, et al. Glucocorticoid receptor mRNA in patients with ulcerative colitis: a study of responders and nonresponders to glucocorticoid therapy. Inflamm Bowel Dis 2001;7:202-9.
42. Leung DY, Hamid Q, Vottero A, et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997;186:1567-74.
43. Kam JC, Szefler SJ, Sura W, et al. Combination of IL-2 and IL-4 reduces glucocorticoid receptor binding affinity and T cell response to glucocorticoids. J Immunol 1993;151:3460-6.
44. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegrin ligand and inhibition of osteoprotegrin production by glucocorticoids in human osteoblastic lineage cell: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999;140:4382-9.
45. Saito JK, Davis JW, Wasnich RD, et al. Users of low-dose glucocorticoids have increased bone loss rates: a longitudinal study. Calcif Tiss Internat 1995;57:115-9.
46. Hyams JS, Moore RE, Leichtner AM, et al. Relationship of type I procollagen to corticosteroid therapy in children with inflammatory bowel disease. J Pediatr 1988;112:893-8.
47. Hyams JS, Treem WR, Carey DE, et al. Comparison of collagen propeptides as growth markers in children with inflammatory bowel disease. Gastroenterology 1991;100:971-5.
48. Levine A, Weizman Z, Broide E, et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003;36:248-52.
49. Levine A, Broide E, Stein M, et al. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children. J Pediatr 2002;140:75-80.
50. Kundhal P, Zachos M, Holmes JL, et al. Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. J Pediatr Gastroenterol Nutr 2001;33:75-80.
51. Heuschkel RB, Menache CC, Megerian JT, et al. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000;31:8-15.
52. Griffiths AM, Ohlsson A, Sherman PM, et al. Meta-analysis of enteral nutrition as primary treatment of active Crohn's disease. Gastroenterology 1995;108:1056-67.
53. Markowitz J, Grancher K, Kohn N, et al. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. Am J Gastroenterol 2002;97:928-32.
54. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-69.
55. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pastemack BS. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980;302: 981-7.
56. Ewe K, Press A, Singe C, Stufler M. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105:367-72.
57. Candy S, Wright JP, Gerber M, Adams G, Gerig M, Goodman R. A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease. Gut 1995;37: 674-8.
58. Markowitz J, Rosa J, Grancher K, et al. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990;99:1347-51.
59. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990;117; 809-14.
60. Bouhnik Y, Lemann M, Mary J-Y, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347;215-9.
61. Kim PS, Zlatanic J, Korelitz BI, et al. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol 1999;94:3254-7.
62. Lemann M, Bouhnik Y, Colombel J-F, et al. Randomized, double-blind, placebo-controlled, multicenter, azathioprine withdrawal trial in Crohn's disease. Gastroenterology 2002;122:A23.
63. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118:1025-30.
64. Kader HA, Wenner WJ Jr, Telega GW, et al. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol. 2000;30:409-13.
65. Dubinsky MC, Yang H, Hassard PV. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122: 904-15.
66. Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit. 2004;26:311-8.
67. Mardini HE, Arnold GL. Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. J Clin Gastroenterol 2003;36:390-5.
68. Cuffari C, Dassopoulos T, Turnbough L, et al. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2:410-7.
69. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;49;665-70.
70. Wright S, Sanders DS, Lobo AJ, et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004;53:1123-8.
71. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
72. Regueiro M, Mardini H. Determination of thiopurine methyl-transferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. J Clin Gastroenterol. 2002;35:240-4.
73. Dewit O, Vanheuverzwyn R, Desager JP, et al. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002;16:79-85.
74. Lowry PW, Frankloin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001;49: 656-64.
75. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
76. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000;342:1627-32.
77. Mack DR, Young R, Kaufman SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998;132: 830-5.
78. Rosh J, Youssef N, Schuckalo S, et al. Efficacy of methotrexate as a maintenance agent in pediatric Crohn's disease. J Pediatr Gastro and Nutr 2003;37:392
79. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
80. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
81. Sands BE, Anderson FH, Bernstein CN, et al. Tnfliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
82. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
83. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999;116:1029-34.
84. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722-9.
85. Rutgeerts P, D' Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999: 117:761-9.
86. Feagan BG, Yan S, Bala M, et al. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003;98:2232-8.
87. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99:91-6.
88. Baldassano R, Braegger CR, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8.
89. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000;137:192-6.
90. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenrerol 2000;95:3189-94.
91. De Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in the Netherlands. J Pediatr Gastroenterol Nutr 2004;39: 46-52.
92. Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003;98:104-11.
93. Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002;97:1458-62.
94. Nikolaus S, Raedler A, Kuhbacker T, et al. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000;356:1475-9.
95. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
96. Miele E, Markowitz JE, Mamula P, et al. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004; 38:502-8.
97. Colombel JF, Loftus EV, Jr., Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
98. Kinney T, Rawlins M, Kozarek R, et al. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 2003;98: 608-12.
99. Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 2003;139: E238-9.
100. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
101. Baecklund E, Ekbom A, Sparen P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Br Med J 1998;317:180-1.
102. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997;40:1581-6.
103. Williams CA, Block DA, Sibley J, et al. Lymphoma and leukemia in rheumatoid arthritis: are they associated with azathioprine, cyclophosphamide, or methotrexate: a matched case-control study in the arthritis, rheumatism, and aging medical information system (ARAMIS) population. J Clin Rheumatol 1996;2:64-72.
104. O'Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-52.
105. Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999;94:3248-53.
106. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risks of lymphoma. Gastroenterology 2000;118:1018-24.
107. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080-7.
108. Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000;95:2308-12.
109. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122:72-7.
110. Ljung T, Karlen P, Schmidt D, et al. Tnfliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53.
111. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18, 572 patients. Arthritis Rheum 2004;50:1740-51.
112. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002;122:1592-608.
113. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor ámonoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48: 35-45,
114. Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004;99:1984-9.
115. Sandborn W, Hanauer S, Panaccione R, et al. Adalimumab, a human anti-TNF ámonoclonal antibody, induces clinical remission and response in patients with moderate to severely active Crohn's disease irrespective of smoking status. Am J Gastroenterol 2004;99:S259.
116. FDA Briefing Document. Available at: http://www.fda.gov/ohrms/dockets/ac/ 03/briefing/3930131_02_A-Abbott-Humira.pdf. Accessed February 28, 2003.
117. Issekutz TB. Inhibition of in vivo lymphocyte migration to inflammation and homing to lymphoid tissues by the TA-2 monoclonal antibody: a likely role for VLA-4 in vivo. J Immunol 1991;147:4178-84.
118. Podolsky DK, Lobb R, King N, et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest 1993;92:372-80.
119. Gordon FH, Lai CWY, Hamilton MI, et al. A randomized placebo-controlled trial of humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-74.
120. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348;24-32.
121. Hyams J, Wilson D, Thomas A, et al. A phase II, multicenter, open-label study of the safety, tolerability, and effectiveness of natalizumab in adolescents with moderately to severely active Crohn's disease. J Pediatr Gastroenterol Nutr 2004;39:S49.
122. Baldassano RN, Han PD, Jeshion WC, et al. Pediatric Crohn's disease: risk factors for postoperative recurrence. Am J Gastroenterol 2001;96:2169-16.
123. Griffiths AM, Wesson DE, Shandling B, et al. Factors influencing postoperative recurrence of Crohn's disease in childhood. Gut 1991;32:491-5.
124. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
125. Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73.
126. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000;118:264-73.
127. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2 year trial. Gastroenterology 2004: 127:723-9.
128. Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology. 2004;127:730-40.
129. Ewe K, Bottger T, Buhr HJ, et al. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. Eur J Gastroenterol Hepatol 1999;11:277-82.
130. Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology 1999;116:294-300.
131. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-9.
132. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient non-adherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003;98:1535-44.